TrialThe New England journal of medicine2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Charles V Pollack et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
343 papers cite itlatest 60 shown
this paperpooled ittrialcites it